Giné Soca, E., Cruz, F. d. l., Jiménez Ubieto, A., López Jimenez, J., Martín García-Sancho, A., Terol, M. J., . . . Group, T. G. (2022). Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
Citación estilo ChicagoGiné Soca, Eva, et al. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial. 2022.
Cita MLAGiné Soca, Eva, et al. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial. 2022.
Precaución: Estas citas no son 100% exactas.